A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild‐type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed...

Full description

Saved in:
Bibliographic Details
Main Authors: Reckamp, Karen L., Giaccone, Giuseppe, Camidge, D. Ross, Gadgeel, Shirish M., Khuri, Fadlo R., Engelman, Jeff A., Koczywas, Marianna, Rajan, Arun, Campbell, Alicyn K., Gernhardt, Diana, Ruiz‐Garcia, Ana, Letrent, Stephen, Liang, Jane, Taylor, Ian, O'Connell, Joseph P., Jänne, Pasi A.
Format: Artigo
Language:Inglês
Published: Wiley 2014
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164026/
https://ncbi.nlm.nih.gov/pubmed/24501009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28561
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items